[Successful treatment of hemothorax with recombinant factor VIIa in a hemophilic child with inhibitor].
rFVIIa is at present the most progressive treatment in different haemorrhages and operations in patients with haemophilia A and a high titre of inhibitor. As apparent from the presented case of a 4-year-old boy with haemorrhage into the pleural cavity, rFVIIa is sufficiently effective to induce haemostasis, while it is safe and has no side-effects. It does not induce systemic activation of haemostasis. Its application requires, due to the high price, that all criteria should be met which were elaborated for the Slovak Republic in the National centre of haemostasis and thrombosis.
Hulíková
M
M
Regionálne centrum hemostázy a trombózy, Kosice.
Galajda
P
P
Kubisz
P
P
D002675:Child, Preschool; D005169:Factor VIII / Q000037:antagonists & inhibitors*; D015942:Factor VIIa / Q000627:therapeutic use*; D006467:Hemophilia A / Q000097:blood / Q000150:complications*; D006491:Hemothorax / Q000628:therapy*; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D005169:Factor VIII; D015942:Factor VIIa